Hypertonic Saline Cuts Bronchiolitis Hospital Admissions

A meta-analysis of 35 randomized trials links nebulized hypertonic saline to lower admission risk in infants with bronchiolitis.

Updated on Nov. 13, 2026 in Asthma

Clear unlabeled saline vial beside a coiled nebulizer tube and small mask on a pale clinical tray under soft daylight.
A meta-analysis of 35 randomized trials of 4,723 infants with bronchiolitis links nebulized hypertonic saline to a 26% lower risk of hospital admission. AI Illustration. Upload story photo >

A systematic review and meta-analysis published October 29, 2026, in ERJ Open Research pooled 35 randomized trials of nebulized hypertonic saline versus normal saline in 4723 infants aged 24 months or younger with acute bronchiolitis. Hypertonic saline was associated with a 26% lower relative risk of hospital admission.

Why it matters

Bronchiolitis is a common cause of hospitalization in young infants, so a lower admission risk could reduce pressure on hospital care for this age group. The findings pool trials that were largely conducted in Asia, so their applicability to other health systems is not established by the extraction.

The meta-analysis pooled 4723 infants, 2411 receiving hypertonic saline and 2312 receiving normal saline, with concentrations of 3%-7%. Symptom scores favored hypertonic saline at 24 hours (SMD 0.48) and 48 hours (SMD 0.53), but the 72-hour difference was not statistically significant.

The players

ERJ Open Research

ERJ Open Research is an open-access journal of the European Respiratory Society that publishes respiratory medicine research.

The details

Researchers searched major databases through February 12, 2025, and compared nebulized hypertonic saline with normal saline (0.9% sodium chloride) in randomized trials. Most included trials tested concentrations between 3% and 7%.

Timeline

  1. February 12, 2025: Database search cutoff for included trials.

  2. October 29, 2026: Study published online in ERJ Open Research.

Health Landscape

Nebulized hypertonic saline has been studied as a low-cost add-on for infant bronchiolitis, and this pooled analysis adds to that body of work published through the European Respiratory Society's ERJ Open Research. The review reports effects on admission risk and symptom scores over defined time windows rather than settling long-term outcomes.

For parents of infants with bronchiolitis, the review suggests nebulized hypertonic saline may reduce the chance of hospital admission compared with normal saline. Any change in practice would depend on clinical guidance and the individual infant's condition.

The takeaway

Hypertonic saline showed symptom benefits at 24 and 48 hours and shorter hospital stays, but the benefit at 72 hours was not statistically significant. Families should discuss nebulizer options with a pediatric clinician rather than changing treatment on their own.

Further reading

Explore more on Asthma to see how respiratory treatments for young children are evaluated.

Source note: This article includes information reported by Medscape.